FDA Drug Safety Approach To Be Questioned At House Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
Principal Deputy Commissioner Joshua Sharfstein is scheduled to go before the House Energy and Commerce Health Subcommittee on March 10.
You may also be interested in...
Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure
Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
Dorgan Drug Importation Amendment Has White House In Thorny Position
An amendment being debated on the Senate floor that would allow consumers to import prescription drugs from other countries creates a particularly thorny situation for the White House: while President Obama was a co-sponsor of the measure when he was still a freshman senator, his support of it now would effectively break the $80 billion deal he brokered with the pharmaceutical industry
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.